NCT02010645View on ClinicalTrials.gov

Eltrombopag With Decitabine in Advanced Myelodysplastic Syndrome (MDS)

PHASE2TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

January 2, 2019

Study Completion Date

January 2, 2019

Conditions
Leukemia
Interventions
DRUG

Eltrombopag

Starting dose of Eltrombopag is 100 mg by mouth daily for each 28 day cycle. East Asians will start at 50 mg by mouth daily for each 28 day cycle.

DRUG

Decitabine

Starting dose of Decitabine is 20 mg/m2 by vein on Days 1-5 for each 28 day cycle.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT02010645 - Eltrombopag With Decitabine in Advanced Myelodysplastic Syndrome (MDS) | Biotech Hunter | Biotech Hunter